据市场消息,Moderna公司将在2027年将年度研发费用削减至36亿-38亿美元。周四,Moderna股价盘前大跌8.19%。
作为一家生物医药公司,研发投入对Moderna长期发展至关重要。研发费用的大幅削减或将影响公司未来的研发动力与成果,投资者担忧公司长期增长前景,从而推动股价出现较大波动。
不过,目标削减研发费用的时间距离现在仍有3年时间。短期内,这一消息可能对股价影响并不太大。市场还需持续关注Moderna公司的具体情况与计划,以及其影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.